⌕
Disc Medicine · IRON · Nasdaq
Tenet 49 · Mixed
Compare
$76.57−0.03%At closeTenet 49 · Mixed
$76.57−0.02 (−0.03%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Disc Medicine (IRON) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is IRON's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 17, 2026 · 06:13 ET
Disc Medicine, Inc. (IRON) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript

Disc Medicine, Inc. (IRON) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript…

IRON 0.0% todayRead at source ↗
● Defense WorldNov 10, 2026 · 03:53 ET
Disc Medicine, Inc. $IRON Holdings Raised by Alps Advisors Inc.

Alps Advisors Inc. lifted its position in shares of Disc Medicine, Inc. (NASDAQ: IRON) by 31.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional…

IRON 0.0% todayRead at source ↗
● GlobeNewsWireNov 5, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update

WATERTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patie…

IRON 0.0% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 09:05 ETCOMPANY'S OWN WORDS
Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting

WATERTOWN, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patie…

IRON 0.0% todayRead at source ↗
● GlobeNewsWireNov 2, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patie…

IRON 0.0% todayRead at source ↗
● GlobeNewsWireOct 20, 2026 · 20:52 ETCOMPANY'S OWN WORDS
Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock

WATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments f…

IRON 0.0% todayRead at source ↗
● GlobeNewsWireOct 19, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants

WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments f…

IRON 0.0% todayRead at source ↗
● Seeking AlphaOct 19, 2026 · 15:53 ET
Disc Medicine, Inc. (IRON) Discusses Topline Results of APOLLO Phase III Trial of Bitopertin in EPP Transcript

Disc Medicine, Inc. (IRON) Discusses Topline Results of APOLLO Phase III Trial of Bitopertin in EPP Transcript…

IRON 0.0% todayRead at source ↗
● BenzingaOct 19, 2026 · 12:33 ET
Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study

Disc Medicine Inc. (NASDAQ:IRON) on Monday reported positive topline results from its APOLLO Phase 3 trial evaluating bitopertin for erythropoietic protoporphyria, or EPP, including X-linked protoporphyria, or XLP.…

IRON 0.0% todayRead at source ↗
● InvezzOct 19, 2026 · 12:23 ET
Disc Medicine stock soars: take profit or buy into strength?

Disc Medicine (IRON) shares ripped higher on Monday morning after the company's experimental blood-disorder treatment, bitopertin, delivered positive Phase 3 results. In its press release, management said the APOLLO clin…

IRON 0.0% todayRead at source ↗
● GuruFocusOct 19, 2026 · 12:14 ET
Disc Medicine (IRON) Achieves Positive Phase 3 Trial Results for EPP Treatment

Disc Medicine (IRON) is experiencing a significant surge today following the announcement of positive results from its pivotal Phase 3 APOLLO trial for bitopert…

IRON 0.0% todayRead at source ↗
● MarketBeatOct 19, 2026 · 12:02 ET
Disc Medicine's Bitopertin Nails Phase III Endpoints, Eyes FDA Resubmission

Disc Medicine NASDAQ: IRON said its Phase III APOLLO trial of investigational bitopertin met both co-primary endpoints and all secondary endpoints in patients with erythropoietic protoporphyria (EPP) and X-linked protopo…

IRON 0.0% todayRead at source ↗
● BarronsOct 19, 2026 · 11:28 ET
Disc Medicine Stock Has Its Best Day Since 2022 as Drug Trial Revives FDA Approval Hopes

Disc Medicine plans to resubmit its blood-disorder drug for FDA approval by year-end after a late-stage trial met all its primary and secondary goals.…

IRON 0.0% todayRead at source ↗
● Proactive InvestorsOct 19, 2026 · 11:08 ET
Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints

Disc Medicine (NASDAQ:IRON), the clinical-stage biopharmaceutical company, surged 38% to $78.24 on Monday after its experimental drug bitopertin met every endpoint in a pivotal phase 3 trial. The APOLLO trial results str…

IRON 0.0% todayRead at source ↗
● ReutersOct 19, 2026 · 08:06 ET
Disc Medicine's rare disease drug succeeds in late-stage trial

Disc Medicine's rare disease drug succeeds in late-stage trial…

IRON 0.0% todayRead at source ↗
● GlobeNewsWireOct 19, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)

Positive APOLLO trial topline results demonstrated statistically significant and clinically meaningful benefit across all study endpoints Successfully met co-primary endpoints of reduction in protoporphyrin IX (PPIX) and…

IRON 0.0% todayRead at source ↗
● GlobeNewsWireOct 18, 2026 · 17:00 ETCOMPANY'S OWN WORDS
Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)

WATERTOWN, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patie…

IRON 0.0% todayRead at source ↗
● Newsfile CorpOct 7, 2026 · 12:53 ET
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

New York, New York--(Newsfile Corp. - October 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm,…

IRON 0.0% todayRead at source ↗
● Newsfile CorpOct 6, 2026 · 12:47 ET
ROSEN, LEADING INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

New York, New York--(Newsfile Corp. - October 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASD…

IRON 0.0% todayRead at source ↗
● GlobeNewsWireOct 5, 2026 · 19:28 ET
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) res…

IRON 0.0% todayRead at source ↗
● Newsfile CorpOct 4, 2026 · 23:16 ET
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

New York, New York--(Newsfile Corp. - October 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASD…

IRON 0.0% todayRead at source ↗
● Newsfile CorpOct 3, 2026 · 22:00 ET
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

New York, New York--(Newsfile Corp. - October 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASD…

IRON 0.0% todayRead at source ↗
● PRNewsWireOct 2, 2026 · 15:55 ET
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

NEW YORK, Oct. 2, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting fro…

IRON 0.0% todayRead at source ↗
● Newsfile CorpSep 30, 2026 · 15:40 ET
ROSEN, A LEADING NATIONAL FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

New York, New York--(Newsfile Corp. - September 30, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (N…

IRON 0.0% todayRead at source ↗
● Newsfile CorpSep 29, 2026 · 15:34 ET
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

New York, New York--(Newsfile Corp. - September 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (N…

IRON 0.0% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA31−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just IRON · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.